We are a development stage, private biotechnology company working to develop iPSC-derived autologous neuron replacement programs for Parkinson’s disease.
Aspen Neuroscience is currently conducting IND-enabling studies for our lead product (ANPD001) which provides an autologous neuron cell replacement therapy targeted at sporadic Parkinson’s disease. Our second product (ANPD002), which provides a gene-corrected autologous neuron therapy, is in the research stage and directed at genetically linked forms of Parkinson’s disease beginning with the most common genetic mutation in the gene encoding glucocerebrosidase (GBA).
Seed & Series A
Aspen was founded in 2018 with $6.5 million in seed funding led by Domain Associates and Axon Ventures and included Alexandria Venture Investments, ARCH Venture Partners, OrbiMed, and Section 32.
In early 2020 the company closed a Series A round of $70 million led by OrbiMed and included ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.
In early 2022, the company closed a Series B round of $147 million. Google Ventures, LYFE Capital and Revelation Partners co-led the investment round with participation from additional new investors ADIA, EDB Investments, MELLON, LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset Capital and NS Investment Co. The raise included significant participation from Series A/Seed investment teams including ARCH Venture Partners, OrbiMed Private Investments, Frazier Healthcare Partners, Alexandria Venture Investments and Section32.
The Series B funding will support the planned studies of the company’s lead product candidate for Parkinson’s Disease, ANPD001, including its patient Screening Cohort study and the upcoming Phase 1/2a clinical trial, post-IND submission to FDA.
For further information, please email us at IR@aspenneuro.com.